Pfizer announced today that it expects about $ 15 billion in sales this year from the vaccine against COVID-19 developed with the German company BioNTech.
The pharmaceutical industry is trying to deliver two billion doses of vaccine at a dizzying pace in 2021 as countries around the world rush to sign supply deals in a bid to control the pandemic that has claimed the lives of more than 2 million people worldwide. .
Pfizer has distributed 65 million doses of the vaccine worldwide and 29 million doses in the US as of January 31. It expects to provide 200 million installments to the US government by the end of May.
The US Centers for Disease Control and Prevention (CDC) says it has distributed nearly 50 million doses of Pfizer and Moderna vaccines against COVID-19 until February 1. Of these, 32 million have been administered and 17 million of these doses were from the Pfizer vaccine, according to CDC data.
The vaccine was among the first to be approved for emergency use in the United States and several other countries, and analysts predict billions in sales.
In the fourth quarter, the vaccine generated $ 154 million in revenue. The company said it expects total revenue of between $ 59,4 billion and $ 61,4 billion for 2021.
The company also revised upwards its earnings estimate for 2021. The company now expects adjusted earnings of $ 3,10 to $ 3,20 per share for 2021 compared to its previous earnings forecast of $ 3 to $ 3,10.
Source: RES-EAP